Aripiprazole Plasma Concentrations Delivered from Two 2-Month Long-Acting Injectable Formulations: An Indirect Comparison-Reference-Cited by-同舟云学术

Aripiprazole Plasma Concentrations Delivered from Two 2-Month Long-Acting Injectable Formulations: An Indirect Comparison

Published:2023-06 Issue: Volume:Volume 19 Page:1409-1416
ISSN:1178-2021
Container-title:Neuropsychiatric Disease and Treatment
language:en
Short-container-title:NDT

Author:

Harlin Matthew^ORCID,Chepke Craig,Larsen Frank^ORCID,Bell Lynum Karimah S,Chumki Sanjeda R,Fitzgerald Heather^ORCID,Such Pedro,Madera-McDonough Jessica,Yildirim Murat,Panni Moeen,Saklad Stephen R^ORCID

Publisher

Informa UK Limited

Reference37 articles.

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed, text rev ed. Washington, DC: American Psychiatric Association; 2022.

2. 20-Year Nationwide Follow-Up Study on Discontinuation of Antipsychotic Treatment in First-Episode Schizophrenia

3. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Schizophrenia. 3rd ed. Washington, DC: American Psychiatric Association; 2021. Available from: https://psychiatryonline.org/doi/pdf/10.1176/appi.books.9780890424841. Accessed August 9, 2022.

4. Medication nonadherence in bipolar disorder: a narrative review

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An overview of the efficacy and safety of brexpiprazole for the treatment of schizophrenia in adolescents;Expert Review of Neurotherapeutics;2024-07-05

2. Evaluating the efficacy and safety of the currently available once-every-two months long-acting injectable formulations of aripiprazole for the treatment of schizophrenia or as a maintenance monotherapy for bipolar I disorder in adults;Expert Review of Neurotherapeutics;2024-02-05

3. Aripiprazole 2-month ready-to-use 960 mg (Ari 2MRTU): review of its possible role in schizophrenia therapy;Current Medical Research and Opinion;2023-12

4. Comment on “Aripiprazole Plasma Concentrations Delivered from Two 2-Month Long-Acting Injectable Formulations: An Indirect Comparison” [Letter];Neuropsychiatric Disease and Treatment;2023-07